Tax Penalty, Patient Market Weigh on Pharma's Price-Cut Decision
Healthcare attorney Melissa Wong was quoted in a Bloomberg Law article about drugmakers preparing to participate in Medicare's new drug price negotiation program. The article discusses the challenges drugmakers face in gathering product data ahead of the October 1, 2023 deadline to decide whether to enter negotiations. Ms. Wong commented that manufactures are unlikely to reject negotiations because of the large patient market.
"These are for therapeutic conditions that are really common amongst the Medicare population," she said. "There could be potential big impacts to patients just by the nature of the drugs that were selected."